Definium Therapeutics, Inc. DFTX

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Quick Ratio 6.17 7.05 3.09 7.94 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Current Ratio 6.29 7.25 3.22 8.16 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Debt/EBITDA 2.21 2.44 0.94 2.25 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡
Debt/Assets 9.22% 7.23% 11.34% 0.03% ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Debt/Equity 0.12 0.09 0.18 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡
Asset Turnover 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Operating CF/Net income 0.72 0.73 0.67 0.88 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Capex/Depreciation 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Depreciation/Fixed assets 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Interest Coverage 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
ROE (64.06%) (68.01%) (83.59%) (37.54%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
ROA (49.52%) (50.94%) (65.01%) (34.01%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
ROIC 0.00% 0.00% 0.00% (469.59%) ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Cash ROIC (16.77%) (14.73%) (33.53%) (17.11%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Return on Tangible Assets (52.12%) (44.77%) (133.66%) (44.32%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Accounts Receivable Turnover ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Accounts Payable Turnover 0.00 0.00 0.00 0.76 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Inventory Turnover 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Average Days of Receivables ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Average Days of Payables 0.00 0.00 0.00 322.74 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Days of Inventory on Hand 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Research and Development Expense of Revenue 0.00% 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡
Selling, General and Administrative Expense of Revenue 0.00% 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Intangible Assets out of Total Assets 0.05 0.07 0.16 0.14 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Share Based Compensation of Revenue 0.00% 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡
Revenue per Share 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Operating CF per Share (1.47) (1.12) (1.64) (1.62) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Capex per Share 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Free Cash Flow per Share (1.47) (1.12) (1.64) (1.62) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash per Share 4.61 3.89 2.55 4.61 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shareholders Equity per Share 3.72 3.43 2.00 4.89 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Interest Debt per Share 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡
Book value per Share 3.72 3.43 2.00 4.89 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Free Cash Flow (131.56) (79.13) (64.36) (50.14) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Working Capital 352.62 242.77 71.63 128.16 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Capital Expenditures ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Current Asset Value 311.55 220.92 57.47 126.98 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Average Receivables ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Average Payables 3.68 3.07 3.12 3.14 ‡‡‡‡‡ ‡‡‡‡‡
Average Assets 371.13 213.35 147.27 167.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Average Common Equity 286.89 159.79 114.53 151.29 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Profit Margin 0.00% 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡